683 Capital Management’s Theriva Biologics TOVX Stock Holding History

683 Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-171	Closed	-$19K	–	181
2019 Q3	$19K	Hold	171	–	–	﹤0.01%	149
2019 Q2	$24K	Hold	171	–	–	﹤0.01%	168
2019 Q1	$29K	Hold	171	–	–	﹤0.01%	161
2018 Q4	$24K	Hold	171	–	–	﹤0.01%	185
2018 Q3	$111K	Hold	171	–	–	0.01%	134
2018 Q2	$359K	Hold	171	–	–	0.02%	114
2018 Q1	$478K	Hold	171	–	–	0.04%	108
2017 Q4	$762K	Buy	+171	New	+$1.07M	0.06%	112

Other funds holding TOVX

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

SCA

Snowden Capital Advisors New York $4.23B AUM 29.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

683 Capital Management's TOVX Position: Q4 2019 in Review

683 Capital Management sold out of Theriva Biologics (TOVX) in Q4 2019, closing a stake of 171 shares — an estimated $19K sold.

683 Capital Management first reported a position in TOVX in Q4 2017 and held it in 8 quarters. The position peaked at $762K in Q4 2017. 17 funds tracked by Wall St. Rank hold TOVX as of Q4 2019.

683 Capital Management reported no remaining Theriva Biologics position as of Q4 2019 after selling out during the quarter.
683 Capital Management sold 171 Theriva Biologics shares in Q4 2019, an estimated $19K.
683 Capital Management first reported a position in Theriva Biologics in Q4 2017 and held it in 8 quarters.
683 Capital Management's Theriva Biologics position peaked at $762K in Q4 2017.
17 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2019.

Based on 683 Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.